Building on the legacy of safe, versatile, and effective intrapulmonary percussive ventilation therapy

The IPV® 1 is a safe and effective airway clearance device that builds on the Percussionaire legacy of IPV therapy with a Unified Connector that supports patient safety, a patient-friendly interface, and the unique efficacy of the Phasitron. Together, these features work to restore gas exchange capacity for patients with respiratory complications, while also enhancing the clinical experience for respiratory patients and their care providers.

IPV Therapy

The trusted solution for secretion clearance, hyperinflation relief, and lung recruitment

Combining percussion, entrainment, and high-velocity flow, Sentec Intrapulmonary Percussive Ventilation Therapy can make a big impact for patients with respiratory complications – restoring gas exchange capacity through the resolution of secretion retention, atelectasis, and hyperinflation & air trapping. This technology offers an effective, safe, well-tolerated airway clearance therapy for diverse patient populations, including those with COPD, bronchiolitis, and neuromuscular diseases.

Uniquely Effective Phasitron

The Phasitron, unique to IPV therapy, utilizes a sliding venturi to enable high-velocity flow, entrainment, and percussion, which work together to mobilize secretions and dynamically respond to patient resistance and compliance.

  • Allows for dynamic response to airway resistance
  • Entrains air to recruit the lungs
  • Enhanced percussions effectively break up secretions and mucus plugs
  • Accesses distal airways beyond obstructions or secretions
  • Mobilizes secretions away from airway walls

New Interface

A new patient-friendly design features a simplified interface that’s easy to use – an improved clinical experience for both healthcare providers and their patients.

  • Simplified controls
  • Familiar display panel
  • Patient-friendly design
  • Portable & lightweight
  • Easy to use, easy to learn

Innovative Unified Connector

The Impulsator is specifically designed for convenient use in home care and outpatient clinics, enabling patients to benefit from ongoing airway clearance therapy and lung rehabilitation in a comfortable environment.

  • The Unified Connector prioritizes patient safety and improves efficiency for clinicians.
Benefits for Patients

Site times up to 8 hours enable low stimulation protocols while continuous CO<sub>2</sub> information helps safely reduce blood draws and heel sticks.

Low operating temperature and customized adhesion options protect fragile skin.

Non airway-dependent CO<sub>2</sub> values are accurate regardless of ventilation modality or severity of lung compromise.

Benefits for Providers

Continuous, accurate CO<sub>2</sub> values paired with site times up to 8 hours let you keep a close eye on these fragile patients while letting them be.

Transcutaneous technology provides accurate CO<sub>2</sub> readings regardless of ventilation strategy, enabling enhanced assessment during de-escalation or accelerations in care or support.

Easy-to-learn technology and processes that enhance ventilatory management for individual patients.

Benefits for Facilities

Transcutaneous CO<sub>2</sub> provides accurate ventilation information where end tidal can’t – even during high frequency and high flow ventilation methods as well as bubble CPAP and spontaneous breathing.

Continuous, accurate CO<sub>2</sub> information allows for the safe reduction of blood draws and heel sticks, reducing hard costs as well as softer costs like pain, blood loss, transfusion, and infection.

<a href=”https://www.ncbi.nlm.nih.gov/pubmed/23107301″ target=”_blank” rel=”noopener”>AARC guidelines</a> recommend transcutaneous monitoring for any patient on high frequency or high flow ventilation, as well as any patient who would benefit from minimal blood draws.

How could IPV therapy make a difference for your patients?

To learn more about IPV Therapy contact us below.


Related Posts

  • Patient Story

    Ella’s Story with IPV Therapy

    Ella lives with nemaline myopathy, a rare genetic disorder affecting approximately 1 in 50,000 births. This condition weakens the skeletal muscles responsible for movement, making everyday tasks like walking, speaking, swallowing, and even breathing uniquely challenging.

  • Evidence Summary

    Restoring Gas Exchange Capacity with Intrapulmonary Percussive Ventilation (IPV) Therapy

    The IPV Therapy Clinical Evidence Brochure offers an overview of key clinical studies that highlight the efficacy and safety of intrapulmonary percussive ventilation (IPV) therapy across diverse patient populations.

  • Clinical Impact Summary

    Intrapulmonary Percussive Ventilation Therapy: Clinical Safety & Effectiveness

    The IPV Therapy Clinical Evidence Brochure offers an overview of key clinical studies that highlight the efficacy and safety of intrapulmonary percussive ventilation (IPV) therapy across diverse patient populations. This brochure provides healthcare professionals with an understanding of the clinical utility and benefits of IPV therapy as demonstrated in the available evidence.